1. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5427-31. doi: 
10.1016/j.bmcl.2006.07.058. Epub 2006 Aug 2.

Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of 
metabolic diseases.

Sasikumar TK(1), Qiang L, Burnett DA, Greenlee WJ, Hawes BE, Kowalski TJ, 
O'Neill K, Spar BD, Weig B.

Author information:
(1)Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 
07033, USA. thavalakulamgar.sasikumar@spcorp.com

A series of novel aminobenzimidazoles was prepared and evaluated for h-MCH-R1 
antagonist properties. Most of the compounds showed excellent h-MCH-R1 binding 
affinity as well as mouse ex vivo binding. Compounds 9 and 18 were active in 
mouse DIO studies at 30mpk.

DOI: 10.1016/j.bmcl.2006.07.058
PMID: 16889961 [Indexed for MEDLINE]
